glp 1 drugs for insulin resistance The Role of Glp-1 Receptor Agonists in with Concomitant Obesity Treatment in Polycystic Ovary Syndrome Comparing Ozempic, Wegovy and Other

doi:10.1001/jama.2021.23619 107

Enteroendocrine cells: a review of their role in brain-gut communication

In a mixed-treatment comparison meta-analysis of randomized controlled trials of GLP-1 receptor agonists (exenatide BID and QW and liraglutide) in overweight or obese patients with type 2 diabetes, mean reductions in body weight were greater than with placebo for exenatide 10 g BID (1.4 kg), exenatide QW (1.6 kg), and liraglutide 1.8 mg (1.5 kg), with no significant differences among these three treatments (24)

That model is now being disrupted

Metformin works in the liver and helps your body use insulin more efficiently, so its side effects look a bit different